|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:ATCCode
|
N02AA03
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
injectable solution
suppository
|
|
gptkbp:bioavailability_(intramuscular)
|
52–62%
|
|
gptkbp:bioavailability_(intravenous)
|
100%
|
|
gptkbp:bioavailability_(oral)
|
30–35%
|
|
gptkbp:bioavailability_(rectal)
|
33%
|
|
gptkbp:brand
|
gptkb:Exalgo
gptkb:Dilaudid
|
|
gptkbp:CASNumber
|
466-99-9
|
|
gptkbp:category
|
analgesic
narcotic
semisynthetic opioid
|
|
gptkbp:chemicalFormula
|
C17H19NO3
|
|
gptkbp:contraindication
|
respiratory depression
acute asthma
paralytic ileus
|
|
gptkbp:developedBy
|
gptkb:Knoll
|
|
gptkbp:discoveredBy
|
1924
|
|
gptkbp:eliminationHalfLife
|
2–3 hours
|
|
gptkbp:excretion
|
kidneys
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Hydromorphone
|
|
gptkbp:IUPACName
|
4,5α-epoxy-3-hydroxy-17-methylmorphinan-6-one
|
|
gptkbp:legalStatus
|
Prescription only
Schedule II controlled substance (US)
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
285.34 g/mol
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:proteinBinding
|
8–19%
|
|
gptkbp:relatedTo
|
gptkb:morphine
gptkb:oxymorphone
hydrocodone
|
|
gptkbp:riskFactor
|
addiction
overdose
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
rectal
|
|
gptkbp:sideEffect
|
nausea
constipation
itching
drowsiness
respiratory depression
|
|
gptkbp:UNII
|
J280872D1O
|
|
gptkbp:usedFor
|
pain management
|
|
gptkbp:bfsParent
|
gptkb:Schedule_II
gptkb:Purdue_Pharma
gptkb:Schedule_II_(US)
|
|
gptkbp:bfsLayer
|
6
|